Company Encyclopedia
View More
name
Cardiol Therapeutics
CRDL.US
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros.
4.654 T
CRDL.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    First Berlin Equity Research Sets Cardiol Therapeutics Price Target at $7.80

    First Berlin Equity Research updated its report on Cardiol Therapeutics, maintaining a BUY rating but lowering the 12-month price target from $8.50 to $7.80. The adjustment follows positive Phase II ARCHER study results for CardiolRx in acute myocarditis, showing reduced left-ventricular mass. Analyst Christian Orquera cited post-financing dilution as a reason for the reduced target.

    Reuters·
    US
    CRDL
    0.00%
    Reuters·
    US
    CRDL
    0.00%

    Cardiol Therapeutics (TSE:CRDL) Shares Down 14.6% - Here's Why

    Cardiol Therapeutics (TSE:CRDL) shares fell 14.6% to C$1.29, with trading volume up 406% from average. The stock's 50-day moving average is C$1.50, and its 200-day average is C$1.65. The company reported a quarterly EPS of C($0.12) and is focused on developing therapies for heart disease. Analysts currently rate the stock as Hold, suggesting other stocks may be better investments.

    Market Beat·
    US
    CRDL
    0.00%
    Market Beat·
    US
    CRDL
    0.00%

    Cardiol Therapeutics (TSE:CRDL) Shares Down 17.2% - Here's What Happened

    Cardiol Therapeutics (TSE:CRDL) shares fell 17.2% during mid-day trading on Monday, trading as low as C$1.24. The stock saw a significant increase in trading volume, with 480,129 shares changing hands. The company has a market cap of C$129 million and reported a quarterly loss of C($0.12) per share. Cardiol Therapeutics focuses on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Despite a Hold rating from analysts, some believe there are better investment opportunities elsewhere.

    Market Beat·
    US
    CRDL
    0.00%
    Market Beat·
    US
    CRDL
    0.00%

    Cardiol Therapeutics Reports Phase II Trial Shows CardiolRx Improves Heart Structure in Acute Myocarditis

    Cardiol Therapeutics Inc. announced positive Phase II trial results for CardiolRx™ in acute myocarditis patients, showing significant improvements in heart structure and safety. The trial demonstrated a reduction in left ventricular mass and balanced adverse event rates between treatment and placebo groups. These findings support further development of CardiolRx™ for inflammatory cardiac conditions, including a Phase III program in recurrent pericarditis.

    Reuters·
    US
    CRDL
    0.00%
    Reuters·
    US
    CRDL
    0.00%

    Cardiol Therapeutics Reports Financial Challenges Amid Clinical Progress

    Cardiol Therapeutics Inc. reported a significant decrease in cash reserves and a net loss of $26.6 million for the nine months ending September 30, 2025. Despite financial challenges, the company is committed to advancing its clinical programs, focusing on anti-inflammatory therapies for heart disease. Operating expenses were reduced, and a recent US$11.4 million financing is expected to support ongoing trials. Management remains optimistic about its lead drug candidate, CardiolRx™, and is exploring strategic opportunities to enhance shareholder value.

    Tip Ranks·
    US
    CRDL
    0.00%
    Tip Ranks·
    US
    CRDL
    0.00%
    © 2025 Longbridge｜Disclaimer